Treatment of small cell lung cancer in academic and community settings: Factors associated with receiving standard therapy and survival

Helen M. Parsons, Linda C. Harlan, Jennifer L. Stevens, Claudio Dansky Ullmann

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

PURPOSE: Small cell lung cancer (SCLC) historically has had poor prognosis. Clinical trials have demonstrated improved survival among patients receiving standard platinum-/etoposide-based chemotherapy. Whereas treatment patterns and outcomes have been evaluated for patients with SCLC in clinical trials, population-based practice patterns are not well known. METHODS: The National Cancer Institute's Patterns of Care study was used to evaluate patient and provider factors associated with standard treatment, clinical trial enrollment, and 12-month relative hazard of death. RESULTS: Among 931 patients with SCLC diagnosed in 2007 in academic and community settings, 72.2% of patients with limited-stage (LS) disease received chemoradiation and 42.2% of patients with extensive-stage (ES) disease received chemotherapy only; the expected treatment scenarios by stage. Less than 1% of the patients enrolled in clinical trials and 2.1% of the patients with LS disease and 3.4% of the patients with ES disease refused any type of treatment. Patients 80 years or older at diagnosis and those with pneumonia/lung collapse were less likely to receive chemoradiation for LS disease. Patients treated in hospitals with residency programs were more likely to receive chemotherapy for ES disease, and patients 80 years or older were less likely to receive chemotherapy for ES disease. Finally, female patients with LS disease, black patients with ES disease, and all patients who received chemotherapy compared to receiving radiation alone or no therapy experienced significantly lower mortality. DISCUSSION: Despite the demonstrated lower mortality, a relatively large proportion of patients with SCLC are not treated with a standard treatment regimen. Future studies should evaluate efforts to promote use of appropriate treatment regimens and encourage clinical trial participation.

Original languageEnglish (US)
Pages (from-to)97-104
Number of pages8
JournalCancer Journal (United States)
Volume20
Issue number2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Survival
Therapeutics
Clinical Trials
Drug Therapy
Pulmonary Atelectasis
National Cancer Institute (U.S.)
Mortality
Etoposide
Internship and Residency
Platinum

Keywords

  • lung cancer
  • small cell
  • survival
  • treatment patterns

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Treatment of small cell lung cancer in academic and community settings : Factors associated with receiving standard therapy and survival. / Parsons, Helen M.; Harlan, Linda C.; Stevens, Jennifer L.; Ullmann, Claudio Dansky.

In: Cancer Journal (United States), Vol. 20, No. 2, 2014, p. 97-104.

Research output: Contribution to journalArticle

Parsons, Helen M. ; Harlan, Linda C. ; Stevens, Jennifer L. ; Ullmann, Claudio Dansky. / Treatment of small cell lung cancer in academic and community settings : Factors associated with receiving standard therapy and survival. In: Cancer Journal (United States). 2014 ; Vol. 20, No. 2. pp. 97-104.
@article{afaed77ffb3e4f49981ad1847d3a730d,
title = "Treatment of small cell lung cancer in academic and community settings: Factors associated with receiving standard therapy and survival",
abstract = "PURPOSE: Small cell lung cancer (SCLC) historically has had poor prognosis. Clinical trials have demonstrated improved survival among patients receiving standard platinum-/etoposide-based chemotherapy. Whereas treatment patterns and outcomes have been evaluated for patients with SCLC in clinical trials, population-based practice patterns are not well known. METHODS: The National Cancer Institute's Patterns of Care study was used to evaluate patient and provider factors associated with standard treatment, clinical trial enrollment, and 12-month relative hazard of death. RESULTS: Among 931 patients with SCLC diagnosed in 2007 in academic and community settings, 72.2{\%} of patients with limited-stage (LS) disease received chemoradiation and 42.2{\%} of patients with extensive-stage (ES) disease received chemotherapy only; the expected treatment scenarios by stage. Less than 1{\%} of the patients enrolled in clinical trials and 2.1{\%} of the patients with LS disease and 3.4{\%} of the patients with ES disease refused any type of treatment. Patients 80 years or older at diagnosis and those with pneumonia/lung collapse were less likely to receive chemoradiation for LS disease. Patients treated in hospitals with residency programs were more likely to receive chemotherapy for ES disease, and patients 80 years or older were less likely to receive chemotherapy for ES disease. Finally, female patients with LS disease, black patients with ES disease, and all patients who received chemotherapy compared to receiving radiation alone or no therapy experienced significantly lower mortality. DISCUSSION: Despite the demonstrated lower mortality, a relatively large proportion of patients with SCLC are not treated with a standard treatment regimen. Future studies should evaluate efforts to promote use of appropriate treatment regimens and encourage clinical trial participation.",
keywords = "lung cancer, small cell, survival, treatment patterns",
author = "Parsons, {Helen M.} and Harlan, {Linda C.} and Stevens, {Jennifer L.} and Ullmann, {Claudio Dansky}",
year = "2014",
doi = "10.1097/PPO.0000000000000039",
language = "English (US)",
volume = "20",
pages = "97--104",
journal = "Cancer Journal from Scientific American",
issn = "1528-9117",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "2",

}

TY - JOUR

T1 - Treatment of small cell lung cancer in academic and community settings

T2 - Factors associated with receiving standard therapy and survival

AU - Parsons, Helen M.

AU - Harlan, Linda C.

AU - Stevens, Jennifer L.

AU - Ullmann, Claudio Dansky

PY - 2014

Y1 - 2014

N2 - PURPOSE: Small cell lung cancer (SCLC) historically has had poor prognosis. Clinical trials have demonstrated improved survival among patients receiving standard platinum-/etoposide-based chemotherapy. Whereas treatment patterns and outcomes have been evaluated for patients with SCLC in clinical trials, population-based practice patterns are not well known. METHODS: The National Cancer Institute's Patterns of Care study was used to evaluate patient and provider factors associated with standard treatment, clinical trial enrollment, and 12-month relative hazard of death. RESULTS: Among 931 patients with SCLC diagnosed in 2007 in academic and community settings, 72.2% of patients with limited-stage (LS) disease received chemoradiation and 42.2% of patients with extensive-stage (ES) disease received chemotherapy only; the expected treatment scenarios by stage. Less than 1% of the patients enrolled in clinical trials and 2.1% of the patients with LS disease and 3.4% of the patients with ES disease refused any type of treatment. Patients 80 years or older at diagnosis and those with pneumonia/lung collapse were less likely to receive chemoradiation for LS disease. Patients treated in hospitals with residency programs were more likely to receive chemotherapy for ES disease, and patients 80 years or older were less likely to receive chemotherapy for ES disease. Finally, female patients with LS disease, black patients with ES disease, and all patients who received chemotherapy compared to receiving radiation alone or no therapy experienced significantly lower mortality. DISCUSSION: Despite the demonstrated lower mortality, a relatively large proportion of patients with SCLC are not treated with a standard treatment regimen. Future studies should evaluate efforts to promote use of appropriate treatment regimens and encourage clinical trial participation.

AB - PURPOSE: Small cell lung cancer (SCLC) historically has had poor prognosis. Clinical trials have demonstrated improved survival among patients receiving standard platinum-/etoposide-based chemotherapy. Whereas treatment patterns and outcomes have been evaluated for patients with SCLC in clinical trials, population-based practice patterns are not well known. METHODS: The National Cancer Institute's Patterns of Care study was used to evaluate patient and provider factors associated with standard treatment, clinical trial enrollment, and 12-month relative hazard of death. RESULTS: Among 931 patients with SCLC diagnosed in 2007 in academic and community settings, 72.2% of patients with limited-stage (LS) disease received chemoradiation and 42.2% of patients with extensive-stage (ES) disease received chemotherapy only; the expected treatment scenarios by stage. Less than 1% of the patients enrolled in clinical trials and 2.1% of the patients with LS disease and 3.4% of the patients with ES disease refused any type of treatment. Patients 80 years or older at diagnosis and those with pneumonia/lung collapse were less likely to receive chemoradiation for LS disease. Patients treated in hospitals with residency programs were more likely to receive chemotherapy for ES disease, and patients 80 years or older were less likely to receive chemotherapy for ES disease. Finally, female patients with LS disease, black patients with ES disease, and all patients who received chemotherapy compared to receiving radiation alone or no therapy experienced significantly lower mortality. DISCUSSION: Despite the demonstrated lower mortality, a relatively large proportion of patients with SCLC are not treated with a standard treatment regimen. Future studies should evaluate efforts to promote use of appropriate treatment regimens and encourage clinical trial participation.

KW - lung cancer

KW - small cell

KW - survival

KW - treatment patterns

UR - http://www.scopus.com/inward/record.url?scp=84897555023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897555023&partnerID=8YFLogxK

U2 - 10.1097/PPO.0000000000000039

DO - 10.1097/PPO.0000000000000039

M3 - Article

C2 - 24667952

AN - SCOPUS:84897555023

VL - 20

SP - 97

EP - 104

JO - Cancer Journal from Scientific American

JF - Cancer Journal from Scientific American

SN - 1528-9117

IS - 2

ER -